Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
|Articles|January 1, 2003
Scan Fan
Author(s)Kevin C. Smith, M.D.
As chair of the scientific program of a medical organization, I have been flooded with abstracts, some of which arrived by mail or fax.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5